# Solventum share price today (Solventum Corporation, SOLV)

> Solventum Corporation's earnings have grown faster than its share price. Earnings per share grew +221.7% in a year while the price moved +22.8%. SOLV · Healthcare · Medical Instruments & Supplies · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/solv

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from fewer quarters than usual
- Price: $84.76 (+22.8% in a year)
- P/E: 10.3× (lower than 51% of the last 2.6 years)
- Revenue (Jun 2026): $2.2 B (+2.2% on a year ago)
- Profit (Jun 2026): $92.0 M (+2.2% on a year ago)
- Operating margin: 9.8% (flat on a year ago)
- ROE: 31%, FY25
- ROIC: 5.5%, against a 7.1% cost of capital: −1.6 points

The main question: yearly earnings per share moved +221.7% while the share price moved +22.8%. ## What is the Solventum share price today? Solventum Corporation's share price was $84.76 at the close on 3 November 2026. It has been rising for 26 weeks. That is 8.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between $63 and $92, and at that close it sat 76% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 1 week in a row. Over the last 2.6 years the share price moved +22% while the S&P 500 moved +44%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Solventum pay? Solventum Corporation pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Solventum on? Solventum is on one of our US lists: S&P 500 companies. [S&P 500 companies](https://www.sectoralpha.in/sp-500-stocks)

## Is Solventum profitable? Solventum Corporation earned $92.0 M of net profit in the Jun 2026 quarter, +2.2% on the same quarter a year earlier. Full-year FY25 profit was $1.6 B. Over 4 years profit has grown 1.6% a year on average. That is 4.2% of the quarter's revenue. The same quarter a year earlier earned $90.0 M. For the full year, FY25 profit was $1.6 B (+224.8% on the year before). Why profit moved: revenue changed +2.2% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +238.2% and revenue −0.9%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does Solventum make, and is it growing? Solventum Corporation reported $2.2 B of revenue in the Jun 2026 quarter, +2.2% on the same quarter a year earlier. Over 4 years it has grown 0.5% a year on average. The last full year, FY25, came in at $8.3 B. The last four reported quarters add to $8.3 B. FY25 revenue was $8.3 B, +0.9% on the year before. Recent pace: the last four quarters grew −0.9% on average, against 0.5% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −0.9%, against +0.6% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +277.4%, against +16.4% a year (accelerating). ## How much of every $100 of sales does Solventum keep? Solventum Corporation's operating margin was 9.8% in the Jun 2026 quarter, about the same as the same quarter a year ago. Across 5 years it has been between 8.1% and 22.9%. The latest quarter is within that range. In the latest quarter it moved +0.0 percentage points on the same quarter a year ago. Why the margin moved: operating margin changed +0.0 percentage points on the year while gross margin changed +4.2 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Solventum's profit turning into cash? Over the last 3 years, 103% of Solventum Corporation's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $369 M of operating cash against $1.6 B of profit. After $379 M of spending on assets, free cash was −$10.0 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Solventum's cash go? Solventum Corporation does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.0 B on assets over the last 3 years. Averaged over those years that is 4.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.0 B over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Solventum's P/E ratio, and how does it compare with its own history? Solventum Corporation's P/E is 10.3×, in the middle of its own history: higher than 49% of past readings. Its usual P/E (the middle reading) is 10.4×, over 2.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +221.7% while the price moved +22.8%. Earnings did better than the price, which pulled the multiple down within its own range. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Solventum business getting better or worse? Solventum Corporation's business is turning around. Profit growth has swung from −64.4% at its low to +277.4%, rising from a low 5 quarters ago, with ROCE falling at 6.9%. This is based on 11 quarters of 3 measures, with some gaps. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Solventum earn on its capital? Solventum Corporation earned a ROE of 31% in FY25. That is up from a low of 11% in FY22. Its return on capital used (ROIC) is 1.6 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 18.7% net margin and 0.58× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 18.7% net margin × 0.58× asset turnover × 2.83× leverage (assets divided by equity) ≈ 30.7% on equity. The margin does most of the work; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 5.5% − 7.1% = −1.6 percentage points. The 7.1% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Solventum have too much debt? Solventum Corporation has total debt of $5.3 B against shareholder equity of $4.8 B as of Jun 2026, so its debt is 1.10× its equity. Year by year, that ratio went from 0.01 in FY21 to 1.04 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Solventum shareholding pattern? 3.4% of Solventum Corporation's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 5.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Solventum from balance-sheet trouble? For Solventum Corporation, the Z-score is 1.74. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.74 is inside the danger zone, so the balance sheet is a real risk. ## How does Solventum rank in its industry? 48.3 out of 100, rank 15 of 30 in Medical Instruments & Supplies, with 71% of the evidence available. Solventum Corporation scores 48.3 out of 100 against the 30 companies it is compared with in Medical Instruments & Supplies, ranking 15. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 17.3 + 12.3 + 10.8 + 7.9 = 48.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Solventum compared with? Solventum ranks 15 of 30 Medical Instruments & Supplies companies on the 4-Factor Sector Score, with 48.3 out of 100. 1. [West Pharmaceutical Services, Inc.](https://www.sectoralpha.in/us/stocks/wst) WST · breaking out · Most evidence points up · 81% evidence 68.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.5/35 · Revenue 12.4% · Profit 15.8% · Operating margin change 1.6 points · 83% evidence Capital efficiency 20.6/25 · ROCE 21.2% · Operating margin 22.5% · 76% evidence Valuation 7.0/20 · P/E 44.9× · PEG 2.65 · 65% evidence Relative strength 17.7/20 · Lead over its industry 15.3% · Lead over S&P 500 26.8% · 1 year 50.2% · 100% evidence · 5 of 12 weeks ahead Exact sum: 23.5 + 20.6 + 7 + 17.7 = 68.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [LeMaitre Vascular, Inc.](https://www.sectoralpha.in/us/stocks/lmat) LMAT · turning · Evidence leans up · 81% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.7/35 · Revenue 11.5% · Profit 40.4% · Operating margin change 3.9 points · 83% evidence Capital efficiency 17.3/25 · ROCE 11.9% · Operating margin 29% · 76% evidence Valuation 14.0/20 · P/E 33.4× · PEG 0.86 · 65% evidence Relative strength 4.1/20 · Lead over its industry -25.2% · Lead over S&P 500 -17.1% · 1 year -7.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 26.7 + 17.3 + 14 + 4.1 = 62.1 · What this means: Earnings are strong; relative strength in its sector is -25.2% and the one-year return is -7.2%. 3. [Intuitive Surgical, Inc.](https://www.sectoralpha.in/us/stocks/isrg) ISRG · breaking out · Evidence leans up · 85% evidence 60.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.8/35 · Revenue 20.4% · Profit 7.7% · Operating margin change 3 points · 95% evidence Capital efficiency 21.4/25 · ROCE 22% · Operating margin 33.3% · 76% evidence Valuation 4.5/20 · P/E 48.6× · PEG 5.33 · 65% evidence Relative strength 8.0/20 · Lead over its industry -17.1% · Lead over S&P 500 -8.6% · 1 year -21.3% · 100% evidence · 4 of 12 weeks ahead Exact sum: 26.8 + 21.4 + 4.5 + 8 = 60.7 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 4. [AtriCure, Inc.](https://www.sectoralpha.in/us/stocks/atrc) ATRC · leader · Evidence leans up · 64% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.2/35 · Revenue 14% · Profit n/a · Operating margin change 10.8 points · 62% evidence Capital efficiency 6.1/25 · ROCE 2.2% · Operating margin 6.3% · 76% evidence Valuation 8.9/20 · P/E 134.3× · PEG n/a · 15% evidence Relative strength 19.6/20 · Lead over its industry 37.3% · Lead over S&P 500 49.6% · 1 year 88.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.2 + 6.1 + 8.9 + 19.6 = 58.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [ResMed Inc.](https://www.sectoralpha.in/us/stocks/rmd) RMD · breaking out · Evidence leans up · 81% evidence 57.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 9.8% · Profit 8.8% · Operating margin change -3 points · 83% evidence Capital efficiency 21.5/25 · ROCE 25.4% · Operating margin 30.9% · 76% evidence Valuation 10.2/20 · P/E 18.5× · PEG 1.91 · 65% evidence Relative strength 8.0/20 · Lead over its industry -14.3% · Lead over S&P 500 -5.8% · 1 year -9.7% · 100% evidence · 11 of 12 weeks ahead Exact sum: 17.8 + 21.5 + 10.2 + 8 = 57.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bausch + Lomb Corporation](https://www.sectoralpha.in/us/stocks/blco) BLCO · turning · Evidence leans up · 64% evidence 56.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 8.8% · Profit n/a · Operating margin change 6.8 points · 62% evidence Capital efficiency 7.2/25 · ROCE 3.4% · Operating margin 7.7% · 76% evidence Valuation 11.5/20 · P/E -18.5× · PEG n/a · 15% evidence Relative strength 16.3/20 · Lead over its industry 3.6% · Lead over S&P 500 14% · 1 year 28.8% · 100% evidence · 8 of 12 weeks ahead Exact sum: 21.4 + 7.2 + 11.5 + 16.3 = 56.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Merit Medical Systems, Inc.](https://www.sectoralpha.in/us/stocks/mmsi) MMSI · quiet · Evidence leans up · 81% evidence 55.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue 10.3% · Profit 22.7% · Operating margin change 2.2 points · 83% evidence Capital efficiency 14.3/25 · ROCE 8.1% · Operating margin 14.5% · 76% evidence Valuation 12.7/20 · P/E 28.4× · PEG 1.22 · 65% evidence Relative strength 6.6/20 · Lead over its industry -7% · Lead over S&P 500 1.8% · 1 year -3.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 22 + 14.3 + 12.7 + 6.6 = 55.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Kestra Medical Technologies, Ltd.](https://www.sectoralpha.in/us/stocks/kmts) KMTS · breaking out · Evidence leans up · 64% evidence 54.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.1/35 · Revenue 63.6% · Profit n/a · Operating margin change 27.5 points · 71% evidence Capital efficiency 3.4/25 · ROCE -48% · Operating margin -121.6% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 15.6/20 · Lead over its industry 4.2% · Lead over S&P 500 14.3% · 1 year 10.6% · 100% evidence · 9 of 12 weeks ahead Exact sum: 25.1 + 3.4 + 10 + 15.6 = 54.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Becton, Dickinson and Company](https://www.sectoralpha.in/us/stocks/bdx) BDX · breaking out · Evidence leans up · 71% evidence 51.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.2/35 · Revenue 5.8% · Profit -40.6% · Operating margin change -1.4 points · 83% evidence Capital efficiency 13.6/25 · ROCE 7.6% · Operating margin 15.7% · 76% evidence Valuation 9.6/20 · P/E 44.3× · PEG n/a · 15% evidence Relative strength 13.6/20 · Lead over its industry -2% · Lead over S&P 500 7.5% · 1 year 11.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 14.2 + 13.6 + 9.6 + 13.6 = 51 · What this means: Relative strength against the index is 7.5%, and revenue and profit growth are weak. 10. [Repligen Corporation](https://www.sectoralpha.in/us/stocks/rgen) RGEN · leader · Evidence leans up · 74% evidence 50.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Revenue 16.5% · Profit n/a · Operating margin change 4.8 points · 62% evidence Capital efficiency 8.9/25 · ROCE 2.3% · Operating margin 9.3% · 76% evidence Valuation 3.7/20 · P/E 185.3× · PEG 8.54 · 65% evidence Relative strength 15.3/20 · Lead over its industry 5% · Lead over S&P 500 15% · 1 year 24.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.6 + 8.9 + 3.7 + 15.3 = 50.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Baxter International Inc.](https://www.sectoralpha.in/us/stocks/bax) BAX · quiet · Evidence leans up · 64% evidence 50.1 out of 100 Growth Capital Valuation Relative
12. [The Cooper Companies, Inc.](https://www.sectoralpha.in/us/stocks/coo) COO · basing · Evidence leans down · 85% evidence 49.5 out of 100 Growth Capital Valuation Relative
13. [STAAR Surgical Company](https://www.sectoralpha.in/us/stocks/staa) STAA · turning · Too little evidence to rank firmly · 58% evidence 49.2 out of 100 Growth Capital Valuation Relative
14. [Avantor, Inc.](https://www.sectoralpha.in/us/stocks/avtr) AVTR · leader · Evidence leans down · 71% evidence 48.7 out of 100 Growth Capital Valuation Relative
15. Solventum Corporation this page SOLV · losing its lead · Evidence leans down · 71% evidence 48.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.3/35 · Revenue -0.9% · Profit 100% · Operating margin change 0 points · 83% evidence Capital efficiency 12.3/25 · ROCE 6% · Operating margin 9.8% · 76% evidence Valuation 10.8/20 · P/E 9.3× · PEG n/a · 15% evidence Relative strength 7.9/20 · Lead over its industry -6.9% · Lead over S&P 500 2.4% · 1 year 18.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 17.3 + 12.3 + 10.8 + 7.9 = 48.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 16. [Alcon Inc.](https://www.sectoralpha.in/us/stocks/alc) ALC · turning · Evidence leans down · 61% evidence 47.0 out of 100 Growth Capital Valuation Relative
17. [Azenta, Inc.](https://www.sectoralpha.in/us/stocks/azta) AZTA · leader · Evidence leans down · 64% evidence 46.6 out of 100 Growth Capital Valuation Relative
18. [AptarGroup, Inc.](https://www.sectoralpha.in/us/stocks/atr) ATR · turning · Evidence leans down · 81% evidence 45.6 out of 100 Growth Capital Valuation Relative
19. [Align Technology, Inc.](https://www.sectoralpha.in/us/stocks/algn) ALGN · quiet · Evidence leans down · 81% evidence 44.1 out of 100 Growth Capital Valuation Relative
20. [Stevanato Group S.p.A.](https://www.sectoralpha.in/us/stocks/stvn) STVN · quiet · Evidence leans down · 81% evidence 43.7 out of 100 Growth Capital Valuation Relative
21. [Envista Holdings Corporation](https://www.sectoralpha.in/us/stocks/nvst) NVST · quiet · Too little evidence to rank firmly · 58% evidence 43.2 out of 100 Growth Capital Valuation Relative
22. [Teleflex Incorporated](https://www.sectoralpha.in/us/stocks/tfx) TFX · turning · Evidence leans down · 71% evidence 42.0 out of 100 Growth Capital Valuation Relative
23. [ICU Medical, Inc.](https://www.sectoralpha.in/us/stocks/icui) ICUI · quiet · Evidence leans down · 64% evidence 37.6 out of 100 Growth Capital Valuation Relative
24. [Medline Inc.](https://www.sectoralpha.in/us/stocks/mdln) MDLN · quiet · Too little evidence to rank firmly · 51% evidence 37.3 out of 100 Growth Capital Valuation Relative
25. [DENTSPLY SIRONA Inc.](https://www.sectoralpha.in/us/stocks/xray) XRAY · basing · Most evidence points down · 64% evidence 31.0 out of 100 Growth Capital Valuation Relative
26. [Warby Parker Inc.](https://www.sectoralpha.in/us/stocks/wrby) WRBY · quiet · Most evidence points down · 64% evidence 30.1 out of 100 Growth Capital Valuation Relative
27. [BioLife Solutions, Inc.](https://www.sectoralpha.in/us/stocks/blfs) BLFS · Too little evidence to rank firmly · 44% evidence 48.0 out of 100 Growth Capital Valuation Relative
28. [Pulse Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/plse) PLSE · leader · Too little evidence to rank firmly · 41% evidence 44.0 out of 100 Growth Capital Valuation Relative
29. [MiniMed Group, Inc.](https://www.sectoralpha.in/us/stocks/mmed) MMED · quiet · Too little evidence to rank firmly · 41% evidence 39.1 out of 100 Growth Capital Valuation Relative
30. [Alamar Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/almr) ALMR · turning · Too little evidence to rank firmly · 28% evidence 38.8 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Instruments & Supplies](https://www.sectoralpha.in/us/sectors/medical-instruments-supplies), all 30 compared on one page. ## Which companies are close to Solventum in size? Solventum is the 7th largest of 38 Medical Instruments & Supplies companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Alcon Inc., ResMed Inc. and West Pharmaceutical Services, Inc. Just below it: Baxter International Inc., The Cooper Companies, Inc. and Repligen Corporation. ### Medical Instruments & Supplies companies close in size

1. [Alcon Inc.](https://www.sectoralpha.in/us/stocks/alc) $35.2 billion
2. [ResMed Inc.](https://www.sectoralpha.in/us/stocks/rmd) $31.9 billion
3. [West Pharmaceutical Services, Inc.](https://www.sectoralpha.in/us/stocks/wst) $28.4 billion
4. Solventum Corporation $14.4 billion
5. [Baxter International Inc.](https://www.sectoralpha.in/us/stocks/bax) $13.2 billion
6. [The Cooper Companies, Inc.](https://www.sectoralpha.in/us/stocks/coo) $11.6 billion
7. [Repligen Corporation](https://www.sectoralpha.in/us/stocks/rgen) $11.4 billion

[All 38 Medical Instruments & Supplies companies, largest first](https://www.sectoralpha.in/us/sectors/medical-instruments-supplies#all-companies)

### Companies close in size in other industries

1. [Futu Holdings Limited](https://www.sectoralpha.in/us/stocks/futu) $14.5 billion · Capital Markets
2. [Check Point Software Technologies Ltd.](https://www.sectoralpha.in/us/stocks/chkp) $14.4 billion · Software - Infrastructure
3. Solventum Corporation $14.4 billion
4. [Carpenter Technology Corporation](https://www.sectoralpha.in/us/stocks/crs) $14.4 billion · Metal Fabrication
5. [Unum Group](https://www.sectoralpha.in/us/stocks/unm) $14.4 billion · Insurance - Life

## What else do people ask about Solventum? ### What were Solventum's latest quarterly results? Solventum Corporation reported revenue of $2.2 B and net profit of $92.0 M for the Jun 2026 quarter. Revenue rose 2.2% and profit rose 2.2% compared with a year earlier. Earnings per share were $0.53. The operating margin was 9.8%, 0.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Solventum's market cap? Solventum Corporation's market capitalisation is $14.4 B at a stock price of $84.76. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Solventum performing? Solventum Corporation's share price has been rising for 26 weeks. In its latest quarter, revenue rose 2.2% and profit rose 2.2% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 1 week running (as of 3 November 2026). ### Will Solventum's stock price go up? This page does not forecast Solventum Corporation's stock price. What it shows instead: the stock price is $84.76, and it has been rising for 26 weeks. Its P/E of 10.3× is higher than 49% of its own last 3 years (as of 3 November 2026). ### Is Solventum's profit real cash? Yes, over the last 3 years, 103% of Solventum Corporation's reported profit came in as cash from operations. The latest year was lower at 24%, so the trend is worth watching. In FY25, operating cash was $369 M against reported profit of $1.6 B. Most of that cash then goes into building new capacity. These are yearly figures (as of 3 November 2026). ### Where is Solventum in its business cycle? Solventum Corporation's FY25 operating margin was 8.1%, against a 5-year range of 8.1% to 22.9%: the low end of its own range, which is often where recoveries start. The latest quarter was 9.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Solventum story? The main question: yearly earnings per share moved +221.7% while the share price moved +22.8%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Solventum a stock worth studying right now? What the numbers show: Solventum Corporation's earnings have grown faster than its share price. Earnings per share grew +221.7% in a year while the price moved +22.8%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- S&P 500 companies: https://www.sectoralpha.in/sp-500-stocks

This is research, not advice. We’re not SEBI-registered.